Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
LRP8 is a receptor for tick-borne encephalitis virus
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Microbiology and Immunology, Albert Einstein College of Medicine, NY, New York, United States.
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
United States Army Medical Research Institute of Infectious Diseases, MD, Fort Detrick, United States; The Geneva Foundation, WA, Tacoma, United States; The Henry M. Jackson Foundation, MD, Bethesda, United States.
Vise andre og tillknytning
2025 (engelsk)Inngår i: Nature, ISSN 0028-0836, E-ISSN 1476-4687Artikkel i tidsskrift (Fagfellevurdert) Epub ahead of print
Abstract [en]

Tick-borne encephalitis virus (TBEV) causes tick-borne encephalitis (TBE), a severe and sometimes life-threatening disease characterized by viral invasion of the central nervous system with symptoms of neuroinflammation1,2. As with other orthoflaviviruses—enveloped, arthropod-borne RNA viruses—host factors required for TBEV entry remain poorly defined. Here we used a genome-scale CRISPR–Cas9-based screen to identify LRP8, an apolipoprotein E and reelin receptor with high expression in the brain, as a TBEV receptor. LRP8 downregulation reduced TBEV infection in human cells, and its overexpression enhanced infection. LRP8 bound directly to the TBEV E glycoprotein and mediated viral attachment and internalization into cells. An LRP8-based soluble decoy blocked infection of human cell lines and neuronal cells and protected mice from lethal TBEV challenge. LRP8’s role as a TBEV receptor has implications for TBEV neuropathogenesis and the development of antiviral countermeasures.

sted, utgiver, år, opplag, sider
Springer Nature, 2025.
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-244874DOI: 10.1038/s41586-025-09500-2Scopus ID: 2-s2.0-105016879708OAI: oai:DiVA.org:umu-244874DiVA, id: diva2:2002830
Forskningsfinansiär
NIH (National Institutes of Health), R01AI132633; R01AI165932; R01AI174584; R21AI182834Marianne and Marcus Wallenberg FoundationRegion StockholmSwedish Research Council, 2020-06249Swedish Research Council, 2021-06602Swedish Research Council, 2020-06224Karolinska InstituteTilgjengelig fra: 2025-10-02 Laget: 2025-10-02 Sist oppdatert: 2025-10-02

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Person

Rosendal, EbbaÖverby, Anna K.

Søk i DiVA

Av forfatter/redaktør
Rosendal, EbbaÖverby, Anna K.
Av organisasjonen
I samme tidsskrift
Nature

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 41 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf